Iris Behrmann

14.3k total citations · 4 hit papers
92 papers, 11.6k citations indexed

About

Iris Behrmann is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Iris Behrmann has authored 92 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 53 papers in Molecular Biology and 37 papers in Immunology. Recurrent topics in Iris Behrmann's work include Cytokine Signaling Pathways and Interactions (56 papers), interferon and immune responses (15 papers) and MicroRNA in disease regulation (9 papers). Iris Behrmann is often cited by papers focused on Cytokine Signaling Pathways and Interactions (56 papers), interferon and immune responses (15 papers) and MicroRNA in disease regulation (9 papers). Iris Behrmann collaborates with scholars based in Germany, Luxembourg and France. Iris Behrmann's co-authors include Peter C. Heinrich, Fred Schaper, Gerhard Müller‐Newen, Serge Haan, Heike M. Hermanns, Lutz Graeve, Peter H. Krammer, Michael Pawlita, Claude Haan and Marcus E. Peter and has published in prestigious journals such as Journal of Biological Chemistry, The EMBO Journal and Blood.

In The Last Decade

Iris Behrmann

90 papers receiving 11.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

2003 2.6k citations Peter C. Heinrich, Iris Behrmann et al. Biochemical Journal profile →
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

1998 1.8k citations Peter C. Heinrich, Iris Behrmann et al. Biochemical Journal profile →
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.

1995 1.7k citations Iris Behrmann, Matthias Germer et al. profile →
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

1992 746 citations Iris Behrmann, Werner Falk et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Behrmann Germany	46	5.9k	5.0k	4.4k	1.9k	1000	92	11.6k
Fred Schaper Germany	40	3.3k 0.6×	5.0k 1.0×	4.3k 1.0×	1.2k 0.6×	1.0k 1.0×	96	9.9k
Koichi Nakajima Japan	46	3.6k 0.6×	4.0k 0.8×	3.8k 0.9×	1.2k 0.6×	648 0.6×	95	9.4k
Tracy A. Willson Australia	43	4.8k 0.8×	5.2k 1.1×	4.3k 1.0×	1.0k 0.5×	904 0.9×	74	11.1k
Jacqueline Bromberg United States	44	6.6k 1.1×	8.6k 1.7×	3.6k 0.8×	2.8k 1.5×	545 0.5×	83	13.5k
Lionel Feigenbaum United States	61	4.5k 0.8×	4.3k 0.9×	9.0k 2.0×	879 0.5×	1.2k 1.2×	123	15.1k
David A. Frank United States	61	5.8k 1.0×	5.5k 1.1×	3.5k 0.8×	1.8k 0.9×	518 0.5×	170	13.2k
Lawrence M. Pfeffer United States	54	5.4k 0.9×	3.2k 0.6×	3.6k 0.8×	3.1k 1.6×	901 0.9×	193	10.7k
Andrew C. Larner United States	47	3.9k 0.7×	4.6k 0.9×	3.8k 0.9×	1.1k 0.6×	603 0.6×	96	8.3k
Massimo Gadina United States	55	3.5k 0.6×	4.1k 0.8×	6.4k 1.5×	794 0.4×	1.1k 1.1×	126	13.2k
Chris Albanese United States	54	10.0k 1.7×	5.9k 1.2×	1.9k 0.4×	2.9k 1.5×	1.1k 1.1×	135	15.5k

Countries citing papers authored by Iris Behrmann

Since Specialization

Citations

This map shows the geographic impact of Iris Behrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Behrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Behrmann more than expected).

Fields of papers citing papers by Iris Behrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Behrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Behrmann. The network helps show where Iris Behrmann may publish in the future.

Co-authorship network of co-authors of Iris Behrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Behrmann. A scholar is included among the top collaborators of Iris Behrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Behrmann. Iris Behrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirchmeyer, Mélanie, Anthoula Gaigneaux, Anita Arslanow, et al.. (2023). Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele. Hepatology Communications. 7(12). 7 indexed citations

Rolvering, Catherine, et al.. (2013). Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. Journal of Cellular and Molecular Medicine. 17(2). 265–276. 13 indexed citations

Schmitt, Manfred, Christiane Margue, Iris Behrmann, & Stephanie Kreis. (2013). MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties. Current Molecular Medicine. 13(4). 572–585. 101 indexed citations

Philippidou, Demetra, Martina Schmitt, Dirk Moser, et al.. (2010). Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma. Cancer Research. 70(10). 4163–4173. 186 indexed citations

Vollmer, Stefan, Claude Haan, & Iris Behrmann. (2010). Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochemical Pharmacology. 80(12). 2066–2073. 12 indexed citations

Entschladen, Frank, Joachim Altschmied, Ria Baumgrass, et al.. (2010). Signal transduction, receptors, mediators and genes: younger than ever - the 13th meeting of the Signal Transduction Society focused on aging and immunology. Cell Communication and Signaling. 8(1). 2–2. 2 indexed citations

Haan, Serge, et al.. (2009). SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 28(34). 3069–3080. 36 indexed citations

Komyod, Waraporn, Markus Böhm, Dieter Metze, Peter C. Heinrich, & Iris Behrmann. (2007). Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line. Molecular Cancer Research. 5(3). 271–281. 50 indexed citations

Kreis, Stephanie, et al.. (2007). Cell Density–Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus Kinases. Molecular Cancer Research. 5(12). 1331–1341. 47 indexed citations

10.

Wellbrock, Claudia, Jessica C. Hassel, Petra Fischer, et al.. (2005). STAT5 Contributes to Interferon Resistance of Melanoma Cells. Current Biology. 15(18). 1629–1639. 54 indexed citations

11.

Behrmann, Iris, Peter C. Heinrich, Hildegard Schmitz-Van de Leur, et al.. (2004). Janus Kinase (Jak) Subcellular Localization Revisited. Journal of Biological Chemistry. 279(34). 35486–35493. 72 indexed citations

12.

Kube, Dieter, Udo Holtick, Martina Vockerodt, et al.. (2001). STAT3 is constitutively activated in Hodgkin cell lines. Blood. 98(3). 762–770. 160 indexed citations

13.

Kortylewski, Marcin, et al.. (2001). Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochemical Journal. 357(1). 297–297. 63 indexed citations

14.

Anhuf, Dirk, Jochen Schmitz, Radoslaw M. Sobota, et al.. (2000). Signal Transduction of IL-6, Leukemia-Inhibitory Factor, and Oncostatin M: Structural Receptor Requirements for Signal Attenuation. The Journal of Immunology. 165(5). 2535–2543. 45 indexed citations

15.

Sommer, Ülrike, Marcin Kortylewski, Claude Haan, et al.. (2000). Termination of IL‐6‐induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Letters. 470(1). 15–19. 23 indexed citations

16.

Haan, Claude, Heike M. Hermanns, Peter C. Heinrich, & Iris Behrmann. (2000). A single amino acid substitution (Trp666→Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. Biochemical Journal. 349(1). 261–261. 19 indexed citations

17.

Behrmann, Iris, Andreas Timmermann, Heike Dahmen, et al.. (1999). Identification of a Leu-Ile internalization motif within the cytoplasmic domain of the leukaemia inhibitory factor receptor. Biochemical Journal. 339(1). 15–19. 26 indexed citations

18.

Krammer, Peter H., Iris Behrmann, Peter T. Daniel, Jens Dhein, & Klaus‐Michael Debatin. (1994). Regulation of apoptosis in the immune system. Current Opinion in Immunology. 6(2). 279–289. 273 indexed citations

19.

Krammer, Peter H., Jens Dhein, Henning Walczak, et al.. (1994). The Role of APO‐1‐Mediated Apoptosis in the Immune System. Immunological Reviews. 142(1). 175–191. 201 indexed citations

20.

Behrmann, Iris, Werner Falk, Michael Pawlita, et al.. (1992). Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.. Journal of Biological Chemistry. 267(15). 10709–10715. 746 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact